Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631614 | 0.89 | FAAH (0.48) | CYP2D6TSHRALDH1A1CYP2C9FAAH | |
| SCHEMBL19631555 | 0.88 | SIGMAR1 (0.49) | CYP2D6TSHRALDH1A1CYP2C9CYP3A4 | |
| SCHEMBL19631617 | 0.87 | CHEK1 (0.39) | CYP2D6TSHRALDH1A1CYP2C9HIF1A | |
| SCHEMBL19631725 | 0.87 | KDM4E (0.47) | ALDH1A1FAAHPRKAA2MEN1KMT2A | |
| SCHEMBL19631655 | 0.85 | PRMT5 (0.39) | CYP2D6TSHRALDH1A1CYP2C9 | |
| SCHEMBL19631613 | 0.85 | GRM4 (0.45) | — | |
| SCHEMBL19631695 | 0.85 | GRM4 (0.38) | — | |
| SCHEMBL19631728 | 0.85 | SMN1; SMN2 (0.51) | CYP2D6TSHRALDH1A1HIF1ASMN1; SMN2 | |
| SCHEMBL19631637 | 0.85 | PRKAA2 (0.48) | CYP2D6TSHRALDH1A1CYP2C9HIF1A | |
| SCHEMBL19631700 | 0.82 | SIGMAR1 (0.47) | CYP2D6TSHRALDH1A1CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | claimed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | claimed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | claimed |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | disclosed |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | disclosed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | disclosed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | disclosed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | disclosed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | disclosed |
| WO-2017198339-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | CYP2D6 420/4885TSHR 380/4885ALDH1A1 2389/4885 |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | CYP2D6 420/4885TSHR 380/4885ALDH1A1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.